Technical Analysis for XENE - Xenon Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade F 10.91 -3.02% -0.34
XENE closed down 3.02 percent on Thursday, August 13, 2020, on 46 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical XENE trend table...

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 0.00%
Stochastic Reached Oversold Weakness 0.00%
Outside Day Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Buy Signal Bullish -3.02%
Oversold Stochastic Weakness -1.09%
Narrow Range Bar Range Contraction -3.28%
NR7 Range Contraction -3.28%
Inside Day Range Contraction -3.28%
Oversold Stochastic Weakness -3.28%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is engaged in discovering and developing therapeutics for orphan indications. The company offers Glybera, a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Its product candidates in development comprise TV-45070, which is in Phase IIb clinical trials for the treatment of osteoarthritis of the knee; and in Phase II proof-of-concept clinical trials for the treatment of postherpetic neuralgia and Erythromelalgia. It is also developing TV-45070 for neuropathic pain indications; and GDC-0276 for the treatment of pain. The company's preclinical product candidates include a sodium channel inhibitor to treat DRAVET SYNDROME, an orphan disorder; XEN801, a stearoyl Co-A desaturase, an inhibitor for the treatment of acne; and small-molecule inhibitors for the treatment of cardiovascular disease. Xenon Pharmaceuticals Inc. has collaboration agreements with Teva Pharmaceutical Industries Ltd., Genentech, Inc., and Merck & Co., Inc. The company was founded in 1996 and is headquartered in Burnaby, Canada.
Chemistry Biopharmaceutical Pain Chemical Compounds Organic Compounds Gene Therapy Osteoarthritis Cardiovascular Disease Analgesics Acne Genentech Treatment Of Osteoarthritis Indoles Lipoprotein Lipase Deficiency Alipogene Tiparvovec Glybera Postherpetic Neuralgia

Is XENE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 18.45
52 Week Low 7.0
Average Volume 170,785
200-Day Moving Average 12.80
50-Day Moving Average 12.22
20-Day Moving Average 11.81
10-Day Moving Average 11.21
Average True Range 0.65
ADX 16.56
+DI 14.87
-DI 23.30
Chandelier Exit (Long, 3 ATRs ) 12.16
Chandelier Exit (Short, 3 ATRs ) 12.59
Upper Bollinger Band 13.29
Lower Bollinger Band 10.34
Percent B (%b) 0.19
BandWidth 24.95
MACD Line -0.41
MACD Signal Line -0.35
MACD Histogram -0.0559
Fundamentals Value
Market Cap 196.34 Million
Num Shares 18 Million
EPS -1.66
Price-to-Earnings (P/E) Ratio -6.57
Price-to-Sales 65.85
Price-to-Book 1.07
PEG Ratio -0.05
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.59
Resistance 3 (R3) 11.64 11.48 11.47
Resistance 2 (R2) 11.48 11.30 11.45 11.43
Resistance 1 (R1) 11.19 11.20 11.11 11.14 11.40
Pivot Point 11.03 11.03 10.99 11.00 11.03
Support 1 (S1) 10.74 10.85 10.66 10.69 10.42
Support 2 (S2) 10.58 10.75 10.55 10.39
Support 3 (S3) 10.29 10.58 10.35
Support 4 (S4) 10.24